CAMP vs IONS
CAMP: CAMP4 is pioneering a novel RNA-targeting platform to upregulate deficient genes in rare genetic diseases, starting with SYNGAP1-related developmental epilepsy. IONS: Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic diseases, now executing independent U.S. launches while generating royalty revenue from major pharma partnerships.
Side-by-side fundamentals
| Metric | CAMP | IONS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.11 | $54.01 | |
| Market cap as of 2026-07-23 | $166M | $8.8B | |
| Net margin as of 2026-07-23 | -7.3% | -30.9% | CAMP higher |
| Gross margin as of 2026-07-23 | +35.8% | +98.3% | IONS higher |
| Operating margin as of 2026-07-23 | -5.4% | -33.3% | CAMP higher |
| ROE as of 2026-07-23 | -194.7% | -58.7% | IONS higher |
| ROA as of 2026-07-23 | -95.6% | -10.1% | IONS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 4.76 | CAMP lower |
| Revenue growth (YoY) as of 2026-07-23 | +5.6% | +47.4% | IONS higher |
| Revenue CAGR (3y) SEC XBRL | +216.1% | +17.1% | CAMP higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | -22.84 | 0.38 | |
| 1-year return as of 2026-07-22 close | +100.6% | +28.5% | CAMP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.